Literature DB >> 2707633

Malignancy in coeliac disease--effect of a gluten free diet.

G K Holmes1, P Prior, M R Lane, D Pope, R N Allan.   

Abstract

Two hundred and ten patients with coeliac disease previously reported from this unit were reviewed at the end of 1985 after a further 11 years of follow up. The initial review at the end of 1974 could not demonstrate that a gluten free diet (GFD) prevented these complications, probably because the time on diet was relatively short. The same series has therefore been kept under surveillance with the particular aim of assessing the effects of diet on malignancy after a further prolonged follow up period. Twelve new cancers have occurred: of which one was a carcinoma of the oesophagus and two lymphomas. Thirty nine cancers developed in 38 patients and of 69 deaths, 33 were the result of malignancy. A two-fold relative risk (RR) of cancer was found and was because of an increased risk of cancer of the mouth and pharynx (RR = 9.7, p less than 0.01, 95% confidence interval (CI) = 2.0-28.3), oesophagus (RR = 12.3, p less than 0.01, CI = 2.5-36.5), and of non-Hodgkin's lymphoma (RR = 42.7, p less than 0.001, CI = 19.6-81.4). The results indicate that for coeliac patients who have taken a GFD for five years or more the risk of developing cancer over all sites is not increased when compared with the general population. The risk is increased, however, in those taking a reduced gluten, or a normal diet, with an excess of cancers of the mouth, pharynx and oesophagus (RR = 22.7, p < 0.001), and also of lymphoma (RR = 77.8, p < 0.001). A significant decreasing trend in the excess morbidity rate over increasing use of a GFD was found. The results are suggestive of a protective role for a GFD against malignancy in coeliac disease and give further support for advising all patients to adhere to a strict GFD for life.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2707633      PMCID: PMC1378455          DOI: 10.1136/gut.30.3.333

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  14 in total

Review 1.  Primary abdominal lymphoma. Presenting manifestation of celiac sprue or complicating dermatitis herpetiformis.

Authors:  H J Freeman; W M Weinstein; T K Shnitka; J R Piercey; R H Wensel
Journal:  Am J Med       Date:  1977-10       Impact factor: 4.965

2.  The jejunal cellular infiltrate in coeliac disease complicated by lymphoma.

Authors:  R Ferguson; P Asquith; W T Cooke
Journal:  Gut       Date:  1974-06       Impact factor: 23.059

3.  Malignancy in adult coeliac disease and idiopathic steatorrhoea.

Authors:  O D Harris; W T Cooke; H Thompson; J A Waterhouse
Journal:  Am J Med       Date:  1967-06       Impact factor: 4.965

4.  Malignancy in a 19-year experience of adult celiac disease.

Authors:  W S Selby; N D Gallagher
Journal:  Dig Dis Sci       Date:  1979-09       Impact factor: 3.199

5.  Coeliac disease and malignancy.

Authors:  C M Swinson; G Slavin; E C Coles; C C Booth
Journal:  Lancet       Date:  1983-01-15       Impact factor: 79.321

6.  Steatorrhea and malignant lymphoma. The relationship of malignant tumors of lymphoid tissue and celiac disease.

Authors:  W I Austad; J S Cornes; K R Gough; C F McCarthy; A E Read
Journal:  Am J Dig Dis       Date:  1967-05

7.  Adenocarcinoma of the upper small bowel complicating coeliac disease.

Authors:  G K Holmes; G I Dunn; R Cockel; V S Brookes
Journal:  Gut       Date:  1980-11       Impact factor: 23.059

8.  Coeliac disease, gluten-free diet, and malignancy.

Authors:  G K Holmes; P L Stokes; T M Sorahan; P Prior; J A Waterhouse; W T Cooke
Journal:  Gut       Date:  1976-08       Impact factor: 23.059

9.  Lymphoma risk in coeliac disease of later life.

Authors:  B T Cooper; G K Holmes; W T Cooke
Journal:  Digestion       Date:  1982       Impact factor: 3.216

10.  Intestinal reticulosis as a complication of idiopathic steatorrhoea.

Authors:  K R GOUGH; A E READ; J M NAISH
Journal:  Gut       Date:  1962-09       Impact factor: 23.059

View more
  177 in total

1.  Serological markers and HLA-DQ2 haplotype among first-degree relatives of celiac patients. Catalonian Coeliac Disease Study Group.

Authors:  C Farré; P Humbert; P Vilar; V Varea; X Aldeguer; J Carnicer; M Carballo; M A Gassull
Journal:  Dig Dis Sci       Date:  1999-11       Impact factor: 3.199

Review 2.  Fortnightly review: coeliac disease.

Authors:  C Feighery
Journal:  BMJ       Date:  1999-07-24

Review 3.  [Diagnosis and therapy of endemic (gluten-sensitive) sprue].

Authors:  S Daum; E O Riecken
Journal:  Med Klin (Munich)       Date:  1998-12-15

4.  Celiac sprue among US military veterans: associated disorders and clinical manifestations.

Authors:  F Delcò; H B El-Serag; A Sonnenberg
Journal:  Dig Dis Sci       Date:  1999-05       Impact factor: 3.199

Review 5.  Endomysial antibody in the diagnosis and management of coeliac disease.

Authors:  M W James; B B Scott
Journal:  Postgrad Med J       Date:  2000-08       Impact factor: 2.401

6.  Measurement of gluten using a monoclonal antibody to a coeliac toxic peptide of A-gliadin.

Authors:  H J Ellis; S Rosen-Bronson; N O'Reilly; P J Ciclitira
Journal:  Gut       Date:  1998-08       Impact factor: 23.059

7.  Increasing incidence of enteropathy-associated T-cell lymphoma in the United States, 1973-2008.

Authors:  Reem Z Sharaiha; Ben Lebwohl; Laura Reimers; Govind Bhagat; Peter H Green; Alfred I Neugut
Journal:  Cancer       Date:  2011-12-13       Impact factor: 6.860

Review 8.  Chronic diarrhea: causes, presentation, and management.

Authors:  D I Mehta; E Lebenthal; U Blecker
Journal:  Indian J Pediatr       Date:  1996 Jul-Aug       Impact factor: 1.967

9.  European and North American populations should be screened for coeliac disease.

Authors:  A Fasano
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

10.  Enteropathy-associated T-cell lymphoma involving the colon and extraintestinal B-cell lymphoma in celiac disease.

Authors:  Shyam Varadarajulu; David Lewin
Journal:  Dig Dis Sci       Date:  2003-07       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.